Primo Biotechnology (“Primo”) has announced a strategic collaboration with SHINE Technologies (“Shine”), a global leader in nuclear medicine manufacturing. The agreement will see Primo acquire exclusive distribution rights for Ilumira™ (nca Lutetium-177, Lu-177) in Taiwan, with additional distribution rights in Japan, Korea and Singapore. The collaboration aims to accelerate the advancement of radioligand therapy (RLT) and improve access to cutting-edge cancer treatments in the Asia-Pacific region.
Ilumira™ offers innovative solutions in nuclear medicine, enabling precise and effective treatment of challenging tumors. Primo’s comprehensive solutions address the growing demand for advanced cancer care, from early diagnosis to late-stage treatment.
Under the partnership, Primo will have priority access to Shine’s therapeutic isotopes, ensuring reliable supply for new nuclear medicine applications. Shine’s Cassiopeia facility, the largest nca in North America. The Lu-177 production site is undergoing expansion to meet growing global demand, strengthening Shine’s position as a key supplier and enhancing Primo’s market presence.
“This partnership marks a crucial step in providing precision and access to medical care for patients across Asia Pacific,” said Dr. Ya-Yao Huang, CEO of Primo Biotechnology. “Our collaboration with Shine will provide a stable supply of high-quality isotopes to advance cancer treatment in the region.”
SOURCE: GlobeNewswire
